Evidence map›Paper›PMID 40396612›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Synthesis,

Mohammed Khaled Bin Break, Siddique Akber Ansari, Ahmed A Katamesh, Najah Albadari, Maali D Alshammari, Hamad M Alkahtani

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammed Khaled Bin BreakDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Siddique Akber AnsariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Ahmed A KatameshDepartment of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Najah AlbadariDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Maali D AlshammariDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Hamad M AlkahtaniDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel chrysin-ferrocene Schiff base (CFSB) was synthesised as a potential anticancer agent. CFSB demonstrated high cytotoxicity against cancer cells with HepG2 (liver) being the most susceptible (IC

Indexed as

Antineoplastic AgentsApoptosisCaspasesDNA Topoisomerases, Type IIFerrous CompoundsFlavonoidsMetallocenesTopoisomerase II InhibitorsCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorG1 Phase Cell Cycle CheckpointsHumansMolecular Docking SimulationMolecular StructureSchiff BasesAntineoplastic AgentsCaspaseschrysinDNA Topoisomerases, Type IIferroceneFerrous CompoundsFlavonoidsMetallocenesSchiff BasesTopoisomerase II InhibitorsCancerchrysin-ferrocenemolecular dynamicstopoisomerasetubulin

Identifiers

PMID40396612
PMCPMC12096666

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.